clinical-genomics
(6)
Delve Bio Built One Test for 68,000 Suspects - Now It Wants Doctors to Use It Before the Guessing Game
The UCSF spinout turned an academic pathogen-hunting assay into a 48-hour clinical service. Its next challenge is bigger than sequencing: persuading hospitals to order one broad test earlier, without pretending every strange read is the answer.
Allelica, Inc.
Allelica is a genomics software company building the tools that move polygenic risk scores (PRS) out of the research lab and into routine clinical care. Its cloud platform lets labs and health systems develop, validate, and apply PRS across multiple ancestries, and its clinical test AbsoluteDx combines rare-variant (monogenic) and genome-wide (polygenic) risk in a single report. The company's stated priority is equity - building risk scores that work for patients regardless of genetic ancestry - and its multi-ancestry coronary artery disease work was cited in the 2026 ACC/AHA cardiovascular prevention guidelines.
Cipherome, Inc.
Cipherome is a San Jose-based clinical genomics and bioinformatics company on a mission to find the drug that works for each individual. Its no-code platform COMPASS lets researchers transform, query, and analyze massive clinical and genomic datasets - like the 500,000-participant UK Biobank - without writing code, while its Xentinel platform uses explainable AI to predict and reduce adverse drug reactions. Backed by roughly $16-23M through a Series B, the 12-person team pairs Silicon Valley software with Seoul National University biomedical-informatics research.
Sentieon
Sentieon builds ultra-fast, highly accurate software for analyzing DNA and RNA sequencing data. Its pipelines - DNAseq, DNAscope, TNseq, and TNscope - replace the open-source GATK workflow with matching or better accuracy while running many times faster on ordinary CPUs, no specialized hardware required. Founded in 2014 and based in the Bay Area, the company has won top honors in multiple precisionFDA and DREAM challenges, and its tools are used by pharma, clinical labs, sequencing platform makers, and genomics researchers worldwide to turn raw reads into trustworthy variant calls quickly and cheaply.
Pleno Inc.
Pleno Inc. is a San Diego multi-omic instrument company rebuilding the economics of biological target detection. Its RAPTOR platform, powered by proprietary Hypercoding technology borrowed from telecommunications signal processing, can detect up to 10,000 targets in a single sample at PCR-like speed and cost. Founded by serial entrepreneur Pieter van Rooyen, the company is moving from R&D into commercial launch with backing from Deerfield Management and Foresite Capital.
Helix
Helix is a San Mateo-based population genomics company that helps health systems, life sciences companies, and public health organizations weave genomic data into everyday patient care. Built around its proprietary Exome+ assay and the first FDA-authorized whole exome sequencing platform, Helix powers large-scale precision health programs at partners like Mayo Clinic and Renown Health, with a research network spanning hundreds of thousands of sequenced participants.